Global E-Health Forum: Designing Personalized Healthcare

11 - 13 October 2011, Hamburg, Germany.
Dr. Eric M. Liederman (Director of Medical Informatics, The Permanente Medical Group, U.S.A.) has confirmed his keynote at this year's Global E-Health Forum. He will present "Balancing Privacy Protection with Patient Care".

Healthcare organizations are under increasing regulatory pressure to improve the quality and safety of care and to protect patient privacy. Electronic Health Records (EHR) provide a vehicle to improve care, however concerns over protecting the system against privacy violations are a significant challenge. Dr. Eric Liederman will discuss how to achieve a balance between protecting privacy and security, and fostering high quality patient care.

Learn how Kaiser Permanente's "trust, but hold accountable" approach using forensic mining of its EHR audit databases, resulted in a > 90% reduction in privacy violations over several weeks. Learn how deterrence methods have also helped clinicians and staff avoid giving in to career-ending temptation.

Canada is Partner Country
Mr. Peter M. Boehm, Ambassador of Canada in Germany is pleased to endorse the Global E-Health Forum in Hamburg. He states: "Developing successful e-health solutions requires combining knowledge and technology in several key areas, including: enabling electronic communications infrastructure; providing remote communities in Canada with access to clinical and non-clinical healthcare professionals through the use of advanced information communications technologies; improving health information systems to support service delivery including virtual health libraries; and upholding the health privacy of patients through high standards of information management and exchange." For full text, please see http://www.global-ehealth-forum.com/canada/.

Transforming healthcare in Canada through e-health, the challenges facing the health system in Canada and the role of information and information technology within a reformed health system - these are the topics Richard C. Alvarez, President and Chief Executive Officer, Canada Health Infoway, will address in his keynote.

Program
The first two conference days at the Hamburg Chamber of Commerce will feature more speakers from all over the globe. Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. The official reception for the conference delegates will take place in the U.S. Consulate General ("the little White House at the lake Alster") on October 11. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups.

Registration
Register by August 30 for a conference fee of Euro 599 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 11, 2011.

For further information, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...